close

Agreements

Date: 0000-00-00

Type of information: Research agreement

Compound: OSE-703 (Effi-3)

Company: OSE Immunotherapeutics (France) Memorial Sloan Kettering Cancer Center (USA - NY)

Therapeutic area: Cancer - Oncology

Type agreement: research

Action mechanism: monoclonal antibody.   OSE-703 (Effi-3) is a humanized monoclonal antibody directed against the extracellular domain of the alpha-chain of the receptor for interleukin-7 (CD127). It is cytotoxic for human cells expressing CD127.

Disease: solid tumors, non-small cell lung cancer (NSCLC)

Details: • On June 12, 2017, Ose Immunotherapeutics announced that the company has entered into a multi-year research collaboration on OSE-703, a cytotoxic monoclonal antibody against the alpha chain of Interleukin-7 Receptor (IL-7R), with Memorial Sloan Kettering Cancer Center (MSK) in New York. The collaboration will support a research program using OSE-703 (Effi-3) conducted by physician-scientist Prasad S. Adusumilli, MD, FACS, a thoracic surgeon with expertise in tumor immunology and a focus on the development of chimeric antigen receptor T-cell (CAR T-cell) immunotherapy. The goal of this research collaboration is to explore IL-7R directed immunotherapy OSE-703 for solid tumors with non-small cell lung cancer (NSCLC) as the primary cancer model. From a large cohort of NSCLCs*, it has been shown that IL-7R was overexpressed in this type of cancer and associated with poor prognosis.

Financial terms:

Latest news:

Is general: Yes